Overview

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Status:
Completed
Trial end date:
2020-05-07
Target enrollment:
Participant gender:
Summary
Phase 1 A: First-in-human phase 1 study to determine safety of NP-G2-044 when given orally on a daily X 28 days followed by a 14 day rest period.
Phase:
Phase 1
Details
Lead Sponsor:
Novita Pharmaceuticals, Inc.
Collaborator:
Translational Drug Development